Genentech-partnered Novome lands $43.5M to push gastrointestinal drug through mid-stage study

Paul Schloesser

Associate Editor

A biotech with connections to Roche’s Genentech has now landed its newest cash infusion.

Microbiome outfit Novome Biotechnologies said Tuesday that it has now secured $43.5 million in new financing via a Series B round. The funds, according to the company, will be used to advance its lead candidate through an ongoing Phase IIa — and advance other candidates for a potential indication in inflammatory bowel disease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Genentech-partnered Novome lands $43.5M to push gastrointestinal drug through mid-stage study

Paul Schloesser

Associate Editor

Unlock this article instantly by becoming a free subscriber.

FDA rolls out long-awaited proposal to overhaul diagnostics regulation

FDA unveils new rare disease pilot program to increase agency-sponsor communications

In the race to get type 1 patients off insulin, focus turns to cell transplants and insulin-producing stem cells

Sen. Bill Cassidy calls on hospitals to provide more information on how they use 340B funds

Exclusive: Former Genentech duo reunites to push Sonoma into the clinic; Ex-Magenta commercial chief heads to Editas

Data Quality 2.0: The Future of Real-World Evidence

Genen­tech-part­nered Novome lands $43.5M to push gas­troin­testi­nal drug through mid-stage study

Paul Schloesser

Associate Editor

Unlock this article instantly by becoming a free subscriber.

FDA rolls out long-await­ed pro­pos­al to over­haul di­ag­nos­tics reg­u­la­tion

FDA un­veils new rare dis­ease pi­lot pro­gram to in­crease agency-spon­sor com­mu­ni­ca­tions

In the race to get type 1 pa­tients off in­sulin, fo­cus turns to cell trans­plants and in­sulin-pro­duc­ing stem cells

Sen. Bill Cas­sidy calls on hos­pi­tals to pro­vide more in­for­ma­tion on how they use 340B funds

Ex­clu­sive: For­mer Genen­tech duo re­unites to push Sono­ma in­to the clin­ic; Ex-Ma­gen­ta com­mer­cial chief heads to Ed­i­tas

Da­ta Qual­i­ty 2.0: The Fu­ture of Re­al-World Ev­i­dence

Genentech-partnered Novome lands $43.5M to push gastrointestinal drug through mid-stage study

FDA rolls out long-awaited proposal to overhaul diagnostics regulation

FDA unveils new rare disease pilot program to increase agency-sponsor communications

In the race to get type 1 patients off insulin, focus turns to cell transplants and insulin-producing stem cells

Sen. Bill Cassidy calls on hospitals to provide more information on how they use 340B funds

Exclusive: Former Genentech duo reunites to push Sonoma into the clinic; Ex-Magenta commercial chief heads to Editas

Data Quality 2.0: The Future of Real-World Evidence